Similar articles

• Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

  Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Grijalva CG, et al. JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6. JAMA. 2011. PMID: 22056398 Free PMC article.
• Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

  Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ. Toh S, et al. Pharmacoepidemiol Drug Saf. 2012 May;21(5):524-34. doi: 10.1002/pds.3238. Epub 2012 Mar 13. Pharmacoepidemiol Drug Saf. 2012. PMID: 22411435 Free PMC article.
• Leishmaniasis in the era of tumor necrosis factor alpha antagonist therapy--a research agenda for Europe.

  Zanger P, Gabrysch S. Zanger P, et al. Euro Surveill. 2013 Jul 25;18(30):20542. doi: 10.2807/1560-7917.es2013.18.30.20542. Euro Surveill. 2013. PMID: 23929182
• Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

  Joyau C, Veyrac G, Dixneuf V, Jolliet P. Joyau C, et al. Clin Exp Rheumatol. 2012 Sep-Oct;30(5):700-6. Epub 2012 Oct 17. Clin Exp Rheumatol. 2012. PMID: 22935567 Review.
• Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

  Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network. Ghabril M, et al. Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Clin Gastroenterol Hepatol. 2013. PMID: 23333219 Free PMC article. Review.